Auxiliary diagnosis and molecular targeted therapy by tight junction related molecule JAM-A in head and neck cancer

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K10817
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Otorhinolaryngology
• Research Institution: Sapporo Medical University
• Principal Investigator: MAKOTO KUROSE 札幌医科大学, 医学部, 講師 (60404696)
• Co-Investigator(Kenkyū-buntansha): 高野 賢一 札幌医科大学, 医学部, 准教授 (70404689)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: Head and neck cancer / squamous cell carcinomas / JAM-A / p63/GATA-3 / HDAC / malignancy

Outline of Final Research Achievements

In the present study, we investigated the possibility about auxiliary diagnosis and targeted therapy of squamous cell carcinomas in head and neck cancer by tight junction related molecule JAM-A. We found high expression of JAM-A at the protein and mRNA levels in head and neck squamous cell carcinoma (HNSCC) tissue. Soluble JAM-A in serum of HNSCC patients was high level compared to the normal. Overexpression of JAM-A in HNSCC cell line Detroit562 was in part regulated via p63/GATA-3. We used inhibitors of histone deacetylase (HDAC). By using HNSCC cell line Detroit562, treatment with a panHDAC inhibitor tricostatin A (TSA) or specific inhibitors of HDAC1 and HDAC6 prevented the invasion, migration and proliferation of cancer cells in vitro. Furthermore, they also inhibited expression of p63 and JAM-A in Detroit562 cells. Taken together, inhibitors of HDAC are available in possible about auxiliary diagnosis and molecular targeted therapy for HNSCC via p63/JAM-A.

Free Research Field

頭頸部外科